<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03779841</url>
  </required_header>
  <id_info>
    <org_study_id>1925-201-008</org_study_id>
    <secondary_id>2017-004399-68</secondary_id>
    <nct_id>NCT03779841</nct_id>
  </id_info>
  <brief_title>Botulinum Toxin Type A (AGN-151607) for the Prevention of Post-operative Atrial Fibrillation in Patients Undergoing Open-chest Cardiac Surgery (NOVA)</brief_title>
  <official_title>A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A (AGN-151607) Injections Into the Epicardial Fat Pads to Prevent Post-Operative Atrial Fibrillation in Patients Undergoing Open-Chest Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, randomized, double-blind, placebo-controlled, parallel group,
      dose-ranging study to evaluate the efficacy and safety of botulinum toxin type A (AGN-151607)
      injections into the epicardial fat pads, foci of ganglionic plexi, to prevent Post-Operative
      Atrial Fibrillation (POAF) in patients undergoing open-chest cardiac surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Anticipated">October 14, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with at least 1 continuous atrial fibrillation (AF) episode ≥ 30 seconds during the first 30 days post-surgery.</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of time spent in AF (AF burden) during the first 30 days post-surgery</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with at least 1 event of symptomatic AF during the first 30 days post-surgery</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first occurrence of AF during the first 30 days post-surgery</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with at least 1 continuous AF episode ≥ 2 minutes during the first 30 days post-surgery</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with at least 1 continuous AF episode ≥ 5 minutes during the first 30 days post-surgery</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with at least 1 continuous AF episode ≥ 30 minutes during the first 30 days post-surgery</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with at least 1 continuous AF episode ≥ 1 hour during the first 30 days post-surgery</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with at least 1 continuous AF episode ≥ 4 hours during the first 30 days post-surgery</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with at least 1 continuous AF episode ≥ 24 hours during the first 30 days post-surgery</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Post-Operative Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>AGN-151607 (250 U)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injections of 50 U will be made into each 1 of 5 fat pads. The total injection volume into each fat pad will be 1 mL. One-time treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AGN-151607 (125 U)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injections of 25 U will be made into each 1 of 5 fat pads. The total injection volume into each fat pad will be 1 mL. One-time treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Injections of placebo will be made into each 1 of 5 fat pads. The total injection volume into each fat pad will be 1 mL. One-time treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGN-151607</intervention_name>
    <description>Injections will be made into each 1 of 5 fat pads. The total injection volume into each fat pad will be 1 mL. One-time treatment.</description>
    <arm_group_label>AGN-151607 (125 U)</arm_group_label>
    <arm_group_label>AGN-151607 (250 U)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Injections of placebo will be made into each 1 of 5 fat pads. The total injection volume into each fat pad will be 1 mL. One-time treatment.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Capable of giving signed informed consent, which includes compliance with the
             requirements and restrictions listed in the informed consent form.

          -  Written informed consent from the participant has been obtained prior to any
             study-related procedures

          -  Written documentation has been obtained in accordance with the relevant country and
             local privacy requirements, where applicable (eg. Written Authorization for Use and
             Release of Health and Research Study Information [US sites] and written Data
             Protection consent (European Union sites).

          -  Participants who are scheduled to undergo open-chest cardiac surgery. Including
             (coronary artery bypass graft (CABG) and/or valve repair/replacement).

          -  A male participant must agree to use contraception until Day 60 and refrain from
             donating sperm during this period.

          -  A female participant is eligible to participate if she is not pregnant (has a negative
             urine pregnancy result prior to randomization) not breastfeeding, and at least 1 of
             the following conditions applies:

          -  Not a woman of childbearing potential (WOCBP).

          -  A WOCBP who agrees to follow the contraceptive guidance until after Day 60.

          -  In sinus rhythm for the last 48 hours prior to surgery (prior history of paroxysmal
             atrial fibrillation (AF) is acceptable).

          -  Willing to wear an electrocardiogram (ECG) patch for 30 days post-surgery and for 7
             days after each study visit

          -  Able, as assessed by the investigator, and willing to follow study instructions and
             likely to complete required study visit.

        Exclusion Criteria:

          -  Any medical condition that may put the participant at increased risk with exposure to
             botulinum toxin type A, including diagnosed muscular dystrophy (eg, Duchenne's
             muscular dystrophy), myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral
             sclerosis, mitochondrial disease, or any other significant disease which might
             interfere with neuromuscular function.

          -  Participants with presence or history of any of the following within 3 months prior to
             the Day 1 visit that may indicate a vulnerable respiratory state per the
             investigator's clinical judgment: aspiration pneumonia, lower respiratory tract
             infections, uncontrolled asthma, severe chronic obstructive pulmonary disease, or
             otherwise compromised respiratory function.

          -  Permanent/persistent atrial fibrillation (AF)

          -  Has a known allergy or sensitivity to any botulinum toxin type A preparation.

          -  Has a known allergy or sensitivity to medical adhesive (eg, ECG patch adhesive;
             hydrogel-based adhesive).

          -  Severe (&gt; 55mm) atrial enlargement

          -  Left ventricular ejection fraction (LVEF) &lt; 25%

          -  Presence or history of symptomatic atrioventricular block &gt; 1st degree within the last
             30 days

          -  Class I or III antiarrhythmic drugs unless proper washout was documented

          -  Botulinum toxin type A (of any serotype) use within 6 months of randomization

          -  Has been immunized for any botulinum toxin type A serotype as determined by
             participant medical history

          -  Preoperative need for inotropes/vasopressors or intra-aortic balloon pump

          -  Prior cardiac surgery

          -  History of ablation for AF

          -  Planned ablation procedure for AF at the time of surgery

          -  Emergency surgery

          -  Current enrollment in an investigational drug or device study or participation in such
             a study within 30 days of entry into this study

          -  Impaired prognosis defined as EuroSCORE II greater than 7% perioperative mortality

          -  Females who are pregnant, nursing, or planning a pregnancy during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William G Ferguson, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Registry Team</last_name>
    <phone>877‐277‐8566</phone>
    <email>IR‐CTRegistration@Allergan.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medstar Heart and Vascular Institute</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>202-877-2958</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>678-843-6094</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>734-232-4297</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03766</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ichan School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mission Hospital</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>828-213-5987</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>919-681-2217</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Medical Center Heart and Vascular Research Organization</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>614-292-0858</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>843-792-1851</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White Research Institute The Heart Hospital Plano</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>469-814-4732</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Utah Division of Cardiothoracic Surgery</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>434-243-3178</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus Wien Universitätsklinik für Chirurgie Klinische Abteilung für Herzchirurgie</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre, University Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire de Cardiologie et de Pneumologie de Québec Universié Laval</name>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>418-656-8711</phone>
      <phone_ext>3797</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montreal Heart University</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>514-376-3330</phone>
      <phone_ext>3496</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHUM</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>514-890-8000</phone>
      <phone_ext>14362</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>CIUSS North of Montreal Island Sacré-Cœur Hospital Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>514-338-2222</phone>
      <phone_ext>3083</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Harburg-Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>21075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Leipzig Heart Institute</name>
      <address>
        <city>Leipzig</city>
        <zip>4289</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asst degli Spegali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>390303385201</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Amsterdam UMC</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord Holland</state>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <state>Utrecht</state>
        <zip>3435 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>8036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Solna</city>
        <state>Stockholm</state>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Orebro University Hospital</name>
      <address>
        <city>Orebro</city>
        <zip>70185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>46 19 6025202</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital</name>
      <address>
        <city>Plymouth</city>
        <state>Devon</state>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>1-752-439-231</phone>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 17, 2018</study_first_submitted>
  <study_first_submitted_qc>December 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2018</study_first_posted>
  <last_update_submitted>June 24, 2020</last_update_submitted>
  <last_update_submitted_qc>June 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

